利妥昔单抗生物类似药与参照利妥昔单抗治疗初治晚期滤泡性淋巴瘤(ASSIST-FL):确证性3期双盲随机对照研究主要结果
ASSIST-FL是一项3期双盲随机对照研究,比较GP2013-CVP与参照利妥昔单抗-CVP在初治晚期滤泡性淋巴瘤患者中的疗效与安全性。主要终点总缓解率等价性成立:GP2013组87% vs 参照利妥昔单抗组88%,差异-0.40%(95%CI -5.94至5.14)。不良事件与严重不良事件两组相似,抗药抗体发生率低且相似。
要点
- GP2013-CVP与R-CVP的总缓解率分别为87%与88%,差异-0.40%(95%CI -5.94至5.14),等价性成立。
- 不良事件发生率两组相似:GP2013-CVP组93% vs R-CVP组91%;严重不良事件23% vs 20%。
- 抗药抗体发生率:GP2013-CVP组2%(5/268) vs R-CVP组1%(3/268)。
核心结论
- GP2013是初治晚期滤泡性淋巴瘤患者可用的利妥昔单抗生物类似药候选。
- 生物类似药的引入提供了额外治疗选择,有望增加利妥昔单抗等有效且挽救生命的生物制剂的可及性。
研究设计与样本
- 3期、多国、双盲、随机对照试验,纳入既往未治疗、晚期(Ann Arbor III或IV期)、WHO组织学分级1、2或3a的滤泡性淋巴瘤成人患者(≥18岁)。
- 按1:1随机分配至8周期GP2013-CVP或R-CVP(联合阶段),缓解者随后接受2年单药维持治疗;随机按滤泡性淋巴瘤国际预后指数风险组和地理区域分层。
- 主要终点为总缓解率的可比性,若整个95%CI在-12%至12%范围内则判定等价;主要终点采用符合方案集分析,该集包括接受至少一次(部分或完全)研究治疗剂量且无重大方案偏离的所有患者。
- 试验注册号ClinicalTrials.gov NCT01419665,正在进行中;2011年12月1日至2015年1月15日筛查858例患者,314例随机分配至GP2013(其中312例接受GP2013),315例分配至参照利妥昔单抗。
- 主要分析的中位随访时间为11.6个月(IQR 5.8-18.2)。
主要发现
- 主要终点总缓解率等价性成立:GP2013组311例中271例(87%) vs 参照利妥昔单抗组313例中274例(88%)达到总缓解,差异-0.40%(95%CI -5.94至5.14)。
- 不良事件与严重不良事件两组相似:GP2013-CVP组312例中289例(93%)发生不良事件、71例(23%)发生严重不良事件;R-CVP组315例中288例(91%)发生不良事件、63例(20%)发生严重不良事件。
- 最常见不良事件为中性粒细胞减少:联合阶段GP2013-CVP组312例中80例(26%) vs R-CVP组315例中93例(30%);维持阶段GP2013-CVP组231例中23例(10%) vs R-CVP组231例中13例(6%)。
- 联合与维持阶段最常见3或4级不良事件为中性粒细胞减少:联合阶段GP2013-CVP组312例中55例(18%) vs R-CVP组315例中65例(21%);维持阶段GP2013-CVP组231例中17例(7%) vs R-CVP组231例中9例(4%)。
- 抗药抗体发生率两组相似:GP2013-CVP组268例中5例(2%) vs R-CVP组268例中3例(1%)。
关键数值与推荐
- 主要终点等价性判定标准:总缓解率差异的整个95%CI在-12%至12%范围内。
- GP2013组总缓解率87%(271/311) vs 参照利妥昔单抗组88%(274/313),差异-0.40%(95%CI -5.94至5.14),等价性成立。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GP2013 is a rituximab biosimilar developed to stringent development guidelines, including non-clinical and preclinical investigations and clinical trials in rheumatoid arthritis and follicular lymphoma. We aimed to compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in patients with follicular lymphoma. METHODS: In this phase 3, multinational, double-blind, randomised, controlled trial, adults (aged 18 years or older) with previously untreated, advanced stage (Ann Arbor stage III or IV) follicular lymphoma of WHO histological grades 1, 2, or 3a were randomly assigned (1:1) using interactive response technology to eight cycles of GP2013-CVP or R-CVP (combination phase), followed by monotherapy maintenance in responders for a 2-year period. Randomisation was stratified by Follicular Lymphoma International Prognostic Index risk group and geographic region. The primary endpoint was comparability in overall response, with equivalence concluded if the entire 95% CI was within a margin of -12% to 12%. The primary endpoint was analysed using the per-protocol set, which included all patients who received at least one (partial or complete) dose of investigational treatment and who did not have any major protocol deviations. The trial is registered with ClinicalTrials.gov, number NCT01419665, and is ongoing. FINDINGS: Between Dec 1, 2011, and Jan 15, 2015, 858 patients were screened for eligibility. 314 patients were randomly assigned to GP2013, of whom 312 were given GP2013, and 315 were assigned to reference rituximab. Median follow-up was 11·6 months (IQR 5·8-18·2) for the primary analysis. The primary endpoint, equivalence of overall response, was met (271 [87%] of 311 patients with GP2013 and 274 [88%] of 313 patients with reference rituximab achieved an overall response; difference -0·40% [95% CI -5·94 to 5·14]). Occurrence of adverse events and serious adverse events was similar between the treatment groups (289 [93%] of 312 patients in the GP2013-CVP group had an adverse event and 71 [23%] of 312 patients had a serious adverse event; 288 [91%] of 315 patients in the R-CVP group had an adverse event and 63 [20%] had a serious adverse event). The most common adverse event was neutropenia (80 [26%] of 312 patients in the GP2013-CVP group and 93 [30%] of 315 patients in the R-CVP group in the combination phase and 23 [10%] of 231 patients in the GP2013-CVP group and 13 [6%] of 231 patients in the R-CVP group in the maintenance phase). The most common grade 3 or 4 adverse event during the combination and maintenance phase was neutropenia (55 [18%] of 312 patients in the GP2013-CVP group and 65 [21%] of 315 patients in the R-CVP group in the combination phase and 17 [7%] of 231 patients in the GP2013-CVP group and nine [4%] of 231 patients in the R-CVP group in the maintenance phase). The occurrence of anti-drug antibodies was similar in the treatment groups (five [2%] of 268 patients in the GP2013-CVP; three [1%] in the R-CVP group). INTERPRETATION: Our results show that GP2013 represents a viable rituximab biosimilar candidate for patients with previously untreated advanced follicular lymphoma. The introduction of biosimilars provides additional therapeutic options with potential to increase access to effective and life-saving biological therapies such as rituximab. FUNDING: Hexal.
引用
- Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017. PMID: 28712941. doi:10.1016/S2352-3026(17)30106-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。